What is William Blair's Estimate for argenex Q2 Earnings?

argenex SE (NASDAQ:ARGX - Free Report) - William Blair lifted their Q2 2025 earnings per share (EPS) estimates for shares of argenex in a report issued on Monday, July 14th. William Blair analyst M. Minter now expects that the company will post earnings per share of $2.90 for the quarter, up from their previous estimate of $2.36. The consensus estimate for argenex's current full-year earnings is $3.13 per share. William Blair also issued estimates for argenex's FY2025 earnings at $12.46 EPS and FY2026 earnings at $25.60 EPS.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million.

ARGX has been the subject of a number of other reports. JMP Securities set a $699.00 target price on shares of argenex in a report on Wednesday, May 14th. Baird R W raised argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $720.00 target price on shares of argenex in a research report on Tuesday, July 1st. Deutsche Bank Aktiengesellschaft upgraded argenex from a "hold" rating to a "buy" rating in a research report on Tuesday, July 8th. Finally, Robert W. Baird upgraded argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price objective on the stock in a research report on Tuesday, May 13th. Nineteen analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, argenex has an average rating of "Buy" and a consensus target price of $728.06.

argenex Stock Down 1.5%

Shares of argenex stock traded down $8.51 during trading hours on Wednesday, reaching $569.42. 331,128 shares of the stock traded hands, compared to its average volume of 333,551. The company has a 50 day moving average price of $563.56 and a 200 day moving average price of $600.69. argenex has a one year low of $457.42 and a one year high of $678.21. The firm has a market capitalization of $34.85 billion, a price-to-earnings ratio of 35.13, a P/E/G ratio of 1.01 and a beta of 0.37.

Institutional Investors Weigh In On argenex

Several large investors have recently added to or reduced their stakes in ARGX. SWS Partners purchased a new stake in shares of argenex in the second quarter valued at approximately $1,803,000. Ballentine Partners LLC lifted its holdings in shares of argenex by 12.7% in the 2nd quarter. Ballentine Partners LLC now owns 558 shares of the company's stock worth $308,000 after buying an additional 63 shares during the period. Norden Group LLC grew its position in shares of argenex by 10.0% during the 2nd quarter. Norden Group LLC now owns 450 shares of the company's stock worth $248,000 after buying an additional 41 shares in the last quarter. Park Avenue Securities LLC increased its stake in shares of argenex by 7.3% during the second quarter. Park Avenue Securities LLC now owns 1,936 shares of the company's stock valued at $1,067,000 after buying an additional 132 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in argenex by 1.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 112,057 shares of the company's stock valued at $61,768,000 after purchasing an additional 1,667 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.